Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.47 |
| ▸ | ULK1 | O75385 | 2/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KHK | P50053 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1534438 | 0.87 | NPC1 (0.53) | JAK3KMT2A | |
| SCHEMBL18094907 | 0.84 | BCL9 (0.48) | ULK1KMT2AKHK | |
| SCHEMBL22644321 | 0.81 | MALT1 (0.58) | ALOX15MEN1LMNAHPGDALOX12 | |
| SCHEMBL29458485 | 0.81 | MALT1 (0.58) | ALOX15MEN1LMNAHPGDALOX12 | |
| Hydrochloric Acid SCHEMBL30664787 | 0.80 | MALT1 (0.57) | ALOX15MEN1LMNAHPGDALOX12 | |
| Hydrochloric Acid SCHEMBL22633065 | 0.80 | MALT1 (0.57) | ALOX15MEN1LMNAHPGDALOX12 | |
| SCHEMBL2451482 | 0.79 | ULK1 (0.56) | ULK1HTT | |
| SCHEMBL21670326 | 0.78 | MGLL (0.52) | ROCK2ULK1ALOX15MEN1LMNA | |
| SCHEMBL18395563 | 0.78 | KMT2A (0.58) | ULK1ALOX15MEN1LMNAHPGD | |
| Hydrochloric Acid SCHEMBL16150007 | 0.78 | ULK1 (0.49) | ULK1ALOX15MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10239832-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20160280643-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. | 2016-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280643-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, UGCG, GBA2 | ROCK2 3469/4885ULK1 2279/4885JAK3 4188/4885 |
| US-10239832-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | GBA1, UGCG, GBA2 | ROCK2 3469/4885ULK1 2279/4885JAK3 4188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.